Page 5 - Cronos Group News Today

Intact Investment Management Inc. trimmed its stake in shares of Cronos Group Inc. (NASDAQ:CRON – Free Report) by 22.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 858,190 shares of the company’s stock after selling 250,110 shares during the period. Intact Investment Management Inc. owned 0.23% […]

These are the potential multibagger cannabis stocks to buy at undervalued levels, as they represent companies poised for stellar growth.

Altria Group, Inc. today reports our 2024 first-quarter business results and reaffirms our guidance for 2024 full-year adjusted diluted earnings per share . “We made meaningful progress in...

MariMed (OTCMKTS:MRMD – Get Free Report) and Cronos Group (NASDAQ:CRON – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk. Volatility and Risk MariMed has a beta of […]

We feel now is a pretty good time to analyse Cronos Group Inc.'s ( TSE:CRON ) business as it appears the company may be...

A history of the rise and fall of cannabis beauty brands and how the category is evolving now with products, spas and more THC-centric companies.

The Nutter Securities Enforcement Update is a periodic update of noteworthy recent securities enforcement activity, settlements, decisions, and charges. We provide brief summaries that...

Canopy Growth's Canada Cannabis business generates the majority of the company's revenue.

Cronos Group (NASDAQ:CRON – Free Report) had its price target hoisted by Bank of America from $2.00 to $2.50 in a research report released on Monday, Benzinga reports. Bank of America currently has an underperform rating on the stock. Cronos Group Stock Down 2.7 % NASDAQ CRON opened at $2.54 on Monday. The company has […]

Cronos Group (NASDAQ:CRON – Get Free Report) had its price target upped by equities research analysts at Bank of America from $2.00 to $2.50 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “underperform” rating on the stock. Bank of America‘s price target suggests a potential downside of 6.37% from […]